Targeting the NR3C1 ‐ ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer
Cancer Science · 2026-11 · 117 (11) · 2953-2966
DOI: 10.1111/cas.70479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 23.07.2026. Verfasst von Jing Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Coenzyme A Ligases, Prostatic Neoplasms, Radiation Tolerance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau.
Abstract (Originalsprache)
Radioresistance in prostate cancer demands innovative sensitization strategies. We identified the glucocorticoid receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) as a key negative regulator of radiosensitivity linked to poor prognosis. NR3C1 transcriptionally upregulates the lipid‐metabolizing enzyme, acyl‐CoA synthetase long‐chain family member 4 (ACSL4), thereby enhancing cell proliferation, migration, and radioresistance. High ACSL4 expression sensitizes cells to ferroptosis inducers that amplify lipid peroxidation and restore radiosensitivity. Using the clinically applicable ferroptosis inducer, dihydroartemisinin (DHA), we found that DHA synergizes with ACSL4 to trigger ferroptosis, sensitizing radioresistant cells and xenografts to radiation. This effect was characterized by elevated lipid peroxidation and was reversed by the ferroptosis inhibitor deferoxamine. Collectively, our study revealed that the NR3C1‐ACSL4 axis regulates lipid peroxidation and promotes radioresistance. Targeting this axis with DHA and using ACSL4 as a biomarker represents a promising preclinical strategy to overcome radioresistance in prostate cancer, pending further clinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, P. R. China.
- The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Xiumei Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau
Zitieren
APA
Yang, J., Chen, P., Zheng, Y., Shi, F., Wang, M., Xu, L., Wei, X., & Wang, X. (2026). Targeting the NR3C1 ‐ ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer. Cancer Science, 117(11), 2953-2966. https://doi.org/10.1111/cas.70479
Vancouver
Yang J, Chen P, Zheng Y, Shi F, Wang M, Xu L, et al. Targeting the NR3C1 ‐ ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer. Cancer Science. 2026;117(11):2953-2966. doi:10.1111/cas.70479
BibTeX
@article{Yang2026,
author = {Yang, Jing and Chen, Puyuan and Zheng, Yawen and Shi, Feiyue and Wang, Min and Xu, Luwei and Wei, Xiaowei and Wang, Xiumei},
title = {Targeting the NR3C1 ‐ ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {2953--2966},
doi = {10.1111/cas.70479}
}
EUVIMED